Store Copy Standard

A working standard for reviewing product page copy before a research compound store goes live.

What this is. A set of review rules derived from the public U.S. Food and Drug Administration enforcement record, specifically from warning letters issued to research compound sellers. Every rule below points to something a regulator actually cited in writing. Nothing here is invented caution.

What this is not. This is not legal advice and it does not replace your counsel. It is a practical checklist for the person reviewing the website before launch. Where this standard and your attorney disagree, your attorney wins.

Who this is for. The person doing the pre-launch compliance pass on the website. No technical background is assumed.

1. Why the advertising review does not cover this

The natural assumption is that if the advertising platform approved the ads, the store is fine. It is not, and the two reviews are not related.

The advertising platform reviews the ad and the page the ad points to. It is protecting its own users and its own policies. Passing that review protects the advertising account.

The regulator reviews the store, and in particular the individual product pages. It is asking a completely different question, and it will look at pages no advertisement ever pointed to.

These are two separate reviews with two separate failure modes. An ad funnel can be perfectly clean while the product pages behind it create the entire problem. In the enforcement actions this standard is built from, the cited material was product page copy, not advertising.

One more thing the reader should know up front: in those actions, the agency stated it had reviewed the websites over a period of roughly three months before writing. Product pages are read over time, and archived. Correcting a page after the fact does not erase what was already recorded.

2. The single test that decides everything

The rule that drives every other rule on this page is intended use.

A product becomes a regulated drug not because of what it is, but because of what the seller's own words show it is meant to do. The statutory language is that a product is a drug if it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or function of the body.

Read that second half again, because it is the part people miss. You do not have to claim you treat a disease. Describing what the material does inside a body is enough on its own.

The disclaimer does not decide this. Your copy does.

This is the most important sentence in this document. In both warning letters that this standard is derived from, the sellers had a research use disclaimer on the page, and the agency addressed it directly and set it aside:

"Despite statements on your product labeling marketing your products for 'Research Use Only,' and 'not intended for human consumption, medical use, or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use."

Gram Peptides, warning letter dated March 31, 2026

Keep the disclaimer. It belongs on every page. But understand what it is: it is a statement of intent that the rest of the page can contradict. When the disclaimer says one thing and the product description says another, the product description is treated as the truth.

A reviewer should never approve a page on the basis that the disclaimer is present.

3. Renaming a compound is not a fix

A common practice in this category is to publish a compound under an abbreviation or an in house code rather than its recognized name.

This does not work, and it is worth knowing exactly how it failed. In one of the two letters, the agency identified the compound, named the seller's substitute label, and connected the two itself, in the letter:

"your website offers 'Retatrutide' (also referred to by your firm as 'GLP-1-R peptide') and 'Tirzepatide' (also referred to by your firm as 'GLP-2 peptide')"

Gram Peptides, warning letter dated March 31, 2026

The second letter did the same thing with a different seller's codes, identifying each one in parentheses beside the seller's label.

The takeaway for a reviewer: an internal code name provides no protection. Do not treat a renamed product as a lower risk page. Review it exactly as if it carried the full recognized name, because that is how it will be read. If the page describes what the compound does in a body, the name it is filed under is irrelevant.

4. The bright lines

These may never appear on a product page. Each one is grounded in specific cited language.

4.1 No human outcome figures

No percentages, averages, or magnitudes describing what happened to people.

Cited, Prime Sciences:

"In one study, weight loss of 25% or more was achieved in 40.4% of patients receiving Cagri compared to 16.2% with semaglutide alone."

Cited, Prime Sciences:

"Participants taking semaglutide lost an average of 15.2% of their initial body weight"

This covers headline statistics, comparison tables, animated counters, percentage bars, and figures presented as "representative" or "for reference." Framing a number as illustrative does not change what it communicates.

4.2 No description of what the material does inside a body

No mechanism of action written in terms of bodily processes.

Cited, Prime Sciences:

"Slowing gastric emptying. Reducing food intake. Modulating postprandial glucose spikes. Inducing satiety (feeling of fullness)."

Cited, Prime Sciences:

"Stimulates the pancreas to produce insulin and reduces the hunger hormone ghrelin"

This is the single most common way a page fails. It reads as neutral science writing, which is exactly why it is easy to approve by accident. It is squarely inside the "structure or function of the body" test in section 2.

4.3 No benefits framing

No section headed benefits, effects, results, advantages, or any equivalent.

Cited, Gram Peptides:

"Benefits of GLP-2 Peptide"

Cited, Gram Peptides:

"Weight Management"

Cited, Gram Peptides:

"Improved Lipid Profiles"

The heading alone was quoted. A reviewer does not need to read the paragraph under a benefits heading to reject it.

4.4 No applications, uses, or indications

No statement of what the compound is for.

Cited, Prime Sciences:

"Application: Research peptide with potential in diabetes management and obesity treatment."

Note the construction carefully. The words "research peptide" and "potential" were both present, and neither helped. A hedge in front of an indication is still an indication.

4.5 Hedged and research voiced phrasing is not a safe harbor

This deserves its own line because it is the most common false comfort.

Cited, Gram Peptides:

"Studied for its ability to lower glucose and support balanced insulin levels."

Cited, Gram Peptides:

"Associated with significant decreases in body weight in both animal and human studies."

Cited, Gram Peptides:

"[D]emonstrated significant potential for reducing body weight, improving glucose handling, and enhancing lipid metabolism."

"Studied for", "associated with", "shown to have potential for", "research suggests", and "in research models" were all in the cited material. They did not convert a claim into a neutral statement. If removing the hedge leaves a claim, the sentence fails. That is the test to apply.

4.6 No naming an approved medicine or brand

Cited, Prime Sciences:

"Ozempic"

Do not name approved medicines, their brands, or their manufacturers anywhere in product copy, including in comparisons, alternatives, or "similar to" phrasing.

4.7 No condition or disease names

Obesity, diabetes, and any other condition should not appear in product copy, including inside category names, filters, navigation labels, page titles, or the page's own web address. A condition name in a category label is a statement of what the products in that category are for.

4.8 No administration or regimen information

No frequency, schedule, quantity per administration, or route. No reference to injection, dosing, cycles, or how long an amount lasts in a body.

Handling instructions are different and are addressed in section 6.

4.9 No human trial identifiers

Do not cite named human clinical trial programs, trial phases, or trial results. Both letters cite human study findings. The Prime Sciences letter goes further and quotes phase 3 results and a named trial program, so a trial name and a phase are both established as citable evidence of intended use.

4.10 No imagery that implies use in a person

No bodies, no before and after, no administration imagery, no medical or clinical settings, and no icons depicting injection or administration. Icons count. A small graphic can carry a claim as effectively as a sentence.

4.11 The web address is copy, and fixing the page does not fix it

Every rule above applies to the page's own web address exactly as it applies to the words on the page. An address ending in "peptide-for-healing" makes a claim, and it makes it in the browser bar, in search results, and in every link anyone ever shares.

This is the rule most likely to be missed, and the reason is mechanical. On the common store platforms, renaming a product does not change its address. The address is set once, when the page is first created, and then it stays. So a reviewer can correct a title, approve the page, and ship an address that still carries the exact claim the title just had removed. Nothing warns you. The page looks fixed.

This is not hypothetical. One of the stores that received a warning letter behind this standard was checked in August 2026, months after the letter. The named products had been removed and the body copy had been scrubbed, and the pages still remaining carried both a title and an address built around what the material was said to do for a person. A site can change at any time, so treat that as an example of the failure and not as a description of any store today.

The fix is two steps, not one:

1. Correct the title and the visible copy.
2. Correct the address as well, and redirect the old address to the new one so existing links keep working.

If the platform will not let you change an address, the page has to be rebuilt at a new one. A page whose address you cannot correct is not a page you can approve.

5. Products and pairings that create risk on their own

A page can fail without a single claim on it, purely because of what is offered alongside it.

Both letters treated reconstitution supplies as part of the problem. In one, a seller offered bacteriostatic water beside its compounds:

"The sale of these products together demonstrates that you intend for your 'Bacteriostatic Water for Injection' to be used in combination for injection. Therefore, your 'Bacteriostatic Water for Injection' is a drug."

Gram Peptides, warning letter dated March 31, 2026

In the other, the seller went further and sold a kit containing both the reconstitution fluid and a syringe. The agency called out the kit specifically.

Practical rules for a reviewer:

• Do not sell reconstitution fluid.
• Do not sell syringes, needles, or any administration supplies.
• Do not sell kits or bundles that combine a compound with either of the above.
• Do not offer any of the above as a free gift, an order incentive, a spend threshold reward, or a promotional add on. Giving it away is not meaningfully different from selling it, and it is also prohibited under common advertising platform policies.
• Watch cross sell and recommendation modules. An automatically generated "frequently bought together" block can create the pairing without anyone choosing to.

6. Grey areas, and how to resolve them

These are the judgment calls a reviewer will actually hit. In every case, resolve toward the material and away from the body.

7. Side by side rewrites

The left column is the shape of language that was cited. The right column is the compliant equivalent. Note that the compliant version is not a softened version of the same claim. It is about a different subject: the material and its documentation, rather than a body.

Product summary

Instead of this shape

This compound influences appetite regulation and metabolic rate, and has demonstrated significant potential for supporting body composition in research models.

Write this

A lyophilized powder supplied in a sealed single use vial. Identity is confirmed by mass spectrometry and purity is quantified by reverse phase high performance liquid chromatography. The certificate of analysis for the exact lot supplied is published on this page.

Section heading

Instead of this shape

Benefits and Applications

Write this

Analytical Specification

Mechanism section

Instead of this shape

Acts on receptors in the body to influence how energy is stored and used.

Delete the section entirely. There is no compliant version of a mechanism section on a product page, because its subject is a body. Replace it with the analytical record: what was tested, by which method, against which acceptance criteria, and what the result was.

Quality statement

Instead of this shape

Pharmaceutical grade material equivalent to what is used clinically.

Write this

Manufactured under documented quality controls and released only after each lot meets its defined acceptance criteria. Prior lot certificates are archived and can be compared directly.

Category label

Instead of this shape

Weight Management Compounds

Write this

Peptide Reference Materials

Product title

Instead of this shape

Compound X for Recovery Research

Write this

Compound X, lyophilized powder, sealed vial

Handling note

Instead of this shape

Prepare the vial before use and store the prepared solution refrigerated between applications.

Write this

Store the sealed vial at the temperature stated on the certificate of analysis. Protect from light and moisture. Do not use material that has been stored outside the stated conditions.

Trust and reassurance block

Instead of this shape

Trusted by thousands who have seen results.

Write this

Every lot is tested by an independent accredited laboratory before release, and the certificate for your lot ships with your order.

Frequently asked question

Instead of this shape

How long before results are typically seen? Most research shows changes within several weeks.

Write this

How do I confirm the material I received matches its certificate? Each vial carries a lot number. Enter that lot number on the certificate page to retrieve the analytical record for that specific lot, including the chromatogram and the identity confirmation.

8. Reviewer checklist

Run this down every product page, one page at a time. The catalog overview page is not a substitute for checking each individual page, because the enforcement record is built on individual product pages.

Reject the page if any of the following is true.

1. Any number describes an effect on people, in any format, including graphs, counters, and progress bars.
2. Any sentence describes what the material does inside a body.
3. There is a heading using the words benefits, effects, results, uses, or applications, or any close equivalent.
4. A condition or disease is named anywhere on the page, including in the page title, the category label, navigation, filters, or the page's web address.
5. An approved medicine or brand is named, including in a comparison.
6. Frequency, schedule, quantity per administration, route, or duration in a body appears anywhere.
7. A named human clinical trial, trial phase, or trial result is referenced.
8. An image or icon depicts a body, an administration, or a clinical setting.
9. Reconstitution fluid, syringes, needles, or a kit containing them is sold, bundled, recommended, or offered as a gift or reward anywhere on the page.
10. A customer review or testimonial on the page describes a personal outcome.
11. Removing a hedging phrase such as "studied for" or "associated with" would leave behind a claim.
12. The page relies on the research use disclaimer to make any of the above acceptable.

Then confirm all of the following are true.

13. The research use statement is present, complete, and legible.
14. The substance of the page is the material and its documentation: identity, purity, analytical method, result, certificate, lot number, storage, and handling.
15. The certificate of analysis on the page corresponds to the lot actually being supplied.
16. The FAQ section on the page has been reviewed to the same standard as the body copy.
17. Automatically generated modules on the page, including recommendations and cross sells, have been checked, because they can introduce a prohibited pairing without an author.
18. The page's web address has been read as carefully as its copy, and where a title was corrected the address was corrected with it and the old address redirected. Renaming a product does not rename its address (section 4.11).

9. When you are not sure

Do not resolve it yourself, and do not resolve it by softening the wording.

Softening is the specific failure this standard exists to prevent. The enforcement record shows hedged, careful, research voiced language being quoted back to the seller. Rewording a claim into a gentler claim leaves a claim.

Escalate instead, and use this test to describe the problem:

Does this sentence tell the reader something about a body, or something about the material?

If it tells the reader something about a body, it does not belong on a product page, regardless of how it is phrased. If a reviewer cannot answer that question about a sentence, that sentence is the escalation.

Hold the page. A delayed launch is recoverable. A published product page is read, and archived, by people you did not invite.

10. The record this standard is built on

Two warning letters issued to research compound sellers by the U.S. Food and Drug Administration, both dated March 31, 2026:

• Gram Peptides, reference 721806
• Prime Sciences, reference 721805

Both are published in the agency's public warning letter database and can be read in full there. Both concern products offered for sale as research materials with research use disclaimers in place. In both, the cited evidence of intended use was drawn from the seller's own website copy, and in both, the disclaimer was addressed and set aside.

The agency stated in both letters that the violations listed were not intended to be a complete statement of the violations that might exist, and that failure to address the matter could lead to further regulatory or legal action.

Every passage presented above as a quotation was checked word for word against the published text of these two letters. Each quoted line is labeled with the letter it came from, so any of them can be located and read in context.

This document reflects the enforcement record as of the date it was written. Enforcement positions change. Review this standard periodically against the current record, and against your counsel's advice.